ROCKVILLE, MD – February 19, 2021 – DP Clinical, Inc., a privately held Contract Research Organization (CRO), announced the database lock of its first COVID-19 clinical trial. Taking place the United States, the goal of the study was to determine a suitable dosage of a drug candidate for the treatment of severe acute respiratory syndrome-related Coronavirus 2 (SARS-CoV-2).

“We are proud to have been selected as the CRO partner to run this study,” said Devinder Poonian, President and CEO of DP Clinical. “DP Clinical is a CRO with significant infectious disease experience, and we worked closely with this Sponsor to meet timelines while remaining flexible — essential to staying ahead of the virus. This was DP Clinical’s first COVID-19 trial, and the company expects more COVID-19-related projects in the near future as sponsors continue to seek out CROs with experience in this indication.”